Denali Therapeutics Inc. (DNLI) — Financial statements
Income statement, balance sheet, and cash flow for Denali Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 331↑204.7% | 108↑122.9% | 49 | |
| Cost of Revenue | 11 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -11 | 0.00↓100.0% | 331↑204.7% | 108↑122.9% | 49 | |
| Operating Expenses | ||||||
| R&D Expenses | 419↑5.6% | 396↓6.5% | 424↑18.2% | 359↑35.2% | 265 | |
| General & Administrative Expenses | 97↓7.9% | 105↑2.0% | 103↑14.2% | 90↑14.4% | 79 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 97↓7.9% | 105↑2.0% | 103↑14.2% | 90↑14.4% | 79 | |
| Other Expenses | 28↑294.5% | -15 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 544↑11.7% | 487↓7.6% | 527↑17.4% | 449↑30.4% | 344 | |
| Total Costs & Expenses | 555↑14.0% | 487↓7.6% | 527↑17.4% | 449↑30.4% | 344 | |
| Operating Results | ||||||
| Operating Income | -555↓14.0% | -487↓147.8% | -197↑42.3% | -341↓15.2% | -296 | |
| Depreciation & Amortization | 15↑64.7% | 9↓46.2% | 17↑61.1% | 10↑20.8% | 9 | |
| EBITDA | -498↓1.0% | -493↓173.9% | -180↑45.5% | -330↓15.0% | -287 | |
| EBIT | -512↓2.1% | -502↓155.2% | -197↑42.3% | -341↓15.2% | -296 | |
| Interest & Other Income | ||||||
| Net Interest Income | 43↓33.6% | 65↑25.5% | 52↑248.6% | 15↑221.5% | 5 | |
| Interest Income | 43↓33.6% | 65↑25.5% | 52↑248.6% | 15↑221.5% | 5 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -43↓395.1% | 15 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 43↓33.6% | 65↑25.5% | 52↑248.6% | 15↑221.5% | 5 | |
| Income Before Tax | -512↓21.2% | -423↓191.1% | -145↑55.5% | -326↓12.0% | -291 | |
| Income Tax Expense | 0.10↑50.0% | 0.07↑126.7% | 0.03↑42.9% | 0.02↑103.7% | -0.58 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -513↓21.2% | -423↓191.1% | -145↑55.5% | -326↓12.2% | -291 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -513↓21.2% | -423↓191.1% | -145↑55.5% | -326↓12.2% | -291 | |
| Bottom-Line Net Income | -513↓21.2% | -423↓191.1% | -145↑55.5% | -326↓12.2% | -291 | |
| EPS (Basic) | -2.97↓15.6% | -2.57↓142.5% | -1.06↑59.2% | -2.60↓8.8% | -2.39 | |
| EPS (Diluted) | -2.97↓15.6% | -2.57↓142.5% | -1.06↑59.2% | -2.60↓8.8% | -2.39 | |
| Weighted Average Shares | 175↑6.7% | 164↑19.7% | 137↑9.4% | 126↑3.3% | 122 | |
| Weighted Average Diluted Shares | 175↑6.7% | 164↑19.7% | 137↑9.4% | 126↑3.3% | 122 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.